Royal Bank Of Canada restated their buy rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a report released on Tuesday morning. They currently have a $64.00 price objective on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. William Blair reaffirmed an outperform rating on shares of Sarepta Therapeutics in a research note on Monday. Nomura reaffirmed a buy rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Robert W. Baird reaffirmed an outperform rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Monday. Finally, Needham & Company LLC reaffirmed a buy rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Sarepta Therapeutics currently has an average rating of Buy and an average target price of $64.34.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.90% during trading on Tuesday, hitting $50.71. The stock had a trading volume of 1,849,492 shares. The stock’s 50-day moving average price is $43.21 and its 200 day moving average price is $36.18. The stock’s market cap is $3.26 billion. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $61.99.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. Sarepta Therapeutics’s quarterly revenue was up 350000.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.19) earnings per share. On average, equities analysts forecast that Sarepta Therapeutics will post ($1.22) EPS for the current year.

WARNING: “Sarepta Therapeutics, Inc. (SRPT) Earns “Buy” Rating from Royal Bank Of Canada” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/06/sarepta-therapeutics-inc-srpt-earns-buy-rating-from-royal-bank-of-canada.html.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Douglas S. Ingram bought 47,058 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the acquisition, the chief executive officer now owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 89,556 shares of company stock worth $3,799,208. Company insiders own 9.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. raised its holdings in Sarepta Therapeutics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock worth $280,000 after purchasing an additional 129 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares during the period. Advisor Group Inc. raised its holdings in shares of Sarepta Therapeutics by 3.2% during the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 326 shares during the period. Legal & General Group Plc raised its holdings in shares of Sarepta Therapeutics by 3.9% during the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after acquiring an additional 663 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Sarepta Therapeutics by 0.8% during the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after acquiring an additional 818 shares during the period. Institutional investors own 65.41% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.